CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

10965	Companies
240137	Keywords
168910	Articles
129233	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/24/2025 at 19:00, 1 year 2 months ago

CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 millions d’euros après exercice intégral de la clause d’extension
CROSSJECT annonce le vif succès de son augmentation de capital à 5,7 millions d’euros après exercice intégral de la clause d’extension pour ZEPIZURE®

Financement Augmentation De Capital Pharmaceutique Crossject ZEPIZURE
PRESS RELEASE

published on 06/24/2025 at 19:00, 1 year 2 months ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 1 year 3 months ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
BRIEF

published on 06/11/2025 at 07:35, 1 year 3 months ago

CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour enfants

Pédiatrie Crossject Auto-injecteur Épilepsie ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year 3 months ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year 3 months ago

CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les crises d'épilepsie chez l'enfant
CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour les crises d'épilepsie chez l'enfant, avec calibration réussie de ZENEO®. Étude clinique menée pour adapter l'injection aux enfants

Crossject Enfant ZENEO® Épilepsie ZEPIZURE® Junior
BRIEF

published on 06/06/2025 at 17:50, 1 year 3 months ago

Publication des droits de vote et actions de Crossject

Droits De Vote Capital Social Actions AMF Crossject
BRIEF

published on 06/06/2025 at 17:50, 1 year 3 months ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
PRESS RELEASE

published on 06/06/2025 at 17:45, 1 year 3 months ago

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
CROSSJECT publie le nombre total de droits de vote et d'actions au 31 mai 2025, incluant les informations sur son capital social et ses activités pharmaceutiques

Droits De Vote Capital Social Pharmaceutique Crossject Urgence
BRIEF

published on 06/04/2025 at 20:26, 1 year 3 months ago

CROSSJECT lance une augmentation de capital de près de 5 millions d'euros

Investissement Augmentation De Capital Pharmaceutique Droit Préférentiel De Souscription ZEPIZURE®

Accesswire

Published on 09/12/2026 at 02:35, 11 hours 15 minutes ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 50 minutes ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 45 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 25 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 50 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

EQS Group

Published on 09/12/2026 at 07:30, 6 hours 20 minutes ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 35 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 40 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 5 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 35 minutes ago

CGTN: How BRICS creates new opportunities for Global South development

Les Echos

Published on 09/11/2026 at 07:00, 1 day 6 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE